The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Abstract
Cisplatin is one of the most widely used chemotherapeutic agents for various solid tumors in the clinic due to its high efficacy and broad spectrum. The antineoplastic activity of cisplatin is mainly due to its ability to cross-link with DNA, thus blocking transcription and replication. Unfortunately, the clinical use of cisplatin is limited by its severe, dose-dependent toxic side effects. There are approximately 40 specific toxicities of cisplatin, among which nephrotoxicity is the most common one. Other common side effects include ototoxicity, neurotoxicity, gastrointestinal toxicity, hematological toxicity, cardiotoxicity, and hepatotoxicity. These side effects together reduce the life quality of patients and require lowering the dosage of the drug, even stopping administration, thus weakening the treatment effect. Few effective measures exist clinically against these side effects because the exact mechanisms of various side effects from cisplatin remain still unclear. Therefore, substantial effort has been made to explore the complicated biochemical processes involved in the toxicology of cisplatin, aiming to identify effective ways to reduce or eradicate its toxicity. This review summarizes and reviews the updated advances in the toxicological research of cisplatin. We anticipate to provide insights into the understanding of the mechanisms underlying the side effects of cisplatin and designing comprehensive therapeutic strategies involving cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pearson, R. G. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00905a001 · Cited by 10,475
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Strasser, A., O'Connor, L., & Dixit, V. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.217 · Cited by 1,351
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,251
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
LOEHRER, P. J., & EINHORN, L. H. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-5-704 · Cited by 947
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Chinese Human Proteome Project (CNHPP) Consortium, Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., et al. (2019) · Nature · doi:10.1038/s41586-019-0987-8 · Cited by 947
Self-citationArany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Interaction of Human DNA Polymerase η with Monoubiquitinated PCNA
Kannouche, P. L., Wing, J., & Lehmann, A. R. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00259-x · Cited by 845
Chemotherapy-Induced Nausea and Vomiting
Hesketh, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706547 · Cited by 827
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
Travis, L. B., Fosså, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji278 · Cited by 823
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
Owens, D. M., & Keyse, S. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210412 · Cited by 777
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Cellular response to endoplasmic reticulum stress: a matter of life or death
Boyce, M., & Yuan, J. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401817 · Cited by 680
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
Cloning and Characterization of Two Human Polyspecific Organic Cation Transporters
GORBOULEV, V., ULZHEIMER, J. C., AKHOUNDOVA, A., ULZHEIMER-TEUBER, I., KARBACH, U., QUESTER, S., BAUMANN, C., LANG, F., BUSCH, A. E., & KOEPSELL, H. (1997) · DNA and Cell Biology · doi:10.1089/dna.1997.16.871 · Cited by 638
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Knight, K. R. G., Kraemer, D. F., & Neuwelt, E. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5355 · Cited by 542
Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity
Chirino, Y. I., & Pedraza-Chaverri, J. (2009) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.09.003 · Cited by 489
Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure
Burne, M. J., Daniels, F., Ghandour, A. E., Mauiyyedi, S., Colvin, R. B., O’Donnell, M. P., & Rabb, H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12080 · Cited by 481
Nox3, a superoxide-generating nadph oxidase of the inner ear
Bánfi, B., Malgrange, B., Knisz, J., Steger, K., Dubois-Dauphin, M., & Krause, K.-H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403046200 · Cited by 467
Intracellular K+ Suppresses the Activation of Apoptosis in Lymphocytes
Hughes, F. M., Bortner, C. D., Purdy, G. D., & Cidlowski, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30567 · Cited by 460
Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
Eastman, A. (1986) · Biochemistry · doi:10.1021/bi00361a026 · Cited by 458
Lieberthal, W., Triaca, V., & Levine, J. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.270.4.f700 · Cited by 449
Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2
Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H.-J., Haier, J., Jaehde, U., Zisowsky, J., & Schlatter, E. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61234-5 · Cited by 448
Ciarimboli, G., Deuster, D., Knief, A., Sperling, M., Holtkamp, M., Edemir, B., Pavenstädt, H., Lanvers-Kaminsky, C., am Zehnhoff-Dinnesen, A., Schinkel, A. H., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090610 · Cited by 444
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
Pinto, A. L., & Lippard, S. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90001-0 · Cited by 437
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?
Carozzi, V. A., Canta, A., & Chiorazzi, A. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.014 · Cited by 431
OXIDANT MECHANISMS IN TOXIC ACUTE RENAL FAILURE*
BALIGA, R., UEDA, N., WALKER, P. D., & SHAH, S. V. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101947 · Cited by 426
Cisplatin is retained in the cochlea indefinitely following chemotherapy
Breglio, A. M., Rusheen, A. E., Shide, E. D., Fernandez, K. A., Spielbauer, K. K., McLachlin, K. M., Hall, M. D., Amable, L., & Cunningham, L. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01837-1 · Cited by 412
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Faubel, S., Lewis, E. C., Reznikov, L., Ljubanovic, D., Hoke, T. S., Somerset, H., Oh, D.-J., Lu, L., Klein, C. L., Dinarello, C. A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119792 · Cited by 399
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Li, L., Huang, L., Sung, S.-S. J., Vergis, A. L., Rosin, D. L., Rose, C. E., Lobo, P. I., & Okusa, M. D. (2008) · Kidney International · doi:10.1038/ki.2008.500 · Cited by 393
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Dong, X., Swaminathan, S., Bachman, L.-A., Croatt, A.-J., Nath, K.-A., & Griffin, M.-D. (2007) · Kidney International · doi:10.1038/sj.ki.5002132 · Cited by 363
Cisplatin Binding Sites on Human Albumin
Ivanov, A. I., Christodoulou, J., Parkinson, J. A., Barnham, K. J., Tucker, A., Woodrow, J., & Sadler, P. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14721 · Cited by 362
A Death-Promoting Role for Extracellular Signal-Regulated Kinase
Zhuang, S., & Schnellmann, R. G. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.107367 · Cited by 355
Regulatory T Cells Suppress Innate Immunity in Kidney Ischemia-Reperfusion Injury
Kinsey, G. R., Sharma, R., Huang, L., Li, L., Vergis, A. L., Ye, H., Ju, S.-T., & Okusa, M. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111160 · Cited by 351
Kalam, K., & Marwick, T. H. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.030 · Cited by 343
siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury
Molitoris, B. A., Dagher, P. C., Sandoval, R. M., Campos, S. B., Ashush, H., Fridman, E., Brafman, A., Faerman, A., Atkinson, S. J., Thompson, J. D., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111204 · Cited by 337
Kruidering, M., Van De Water, B., De Heer, E., Mulder, G. J., & Nagelkerke, J. F. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36493-6 · Cited by 325
Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons
Podratz, J. L., Knight, A. M., Ta, L. E., Staff, N. P., Gass, J. M., Genelin, K., Schlattau, A., Lathroum, L., & Windebank, A. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.017 · Cited by 320
Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells
Townsend, D. M., Deng, M., Zhang, L., Lapus, M. G., & Hanigan, M. H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000042803.28024.92 · Cited by 317
TLR4 Signaling Mediates Inflammation and Tissue Injury in Nephrotoxicity
Zhang, B., Ramesh, G., Uematsu, S., Akira, S., & Reeves, W. B. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007090982 · Cited by 317
Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis
Shiraishi, F., Curtis, L. M., Truong, L., Poss, K., Visner, G. A., Madsen, K., Nick, H. S., & Agarwal, A. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.278.5.f726 · Cited by 315
Zhang, B., Ramesh, G., Norbury, C. C., & Reeves, W. B. (2007) · Kidney International · doi:10.1038/sj.ki.5002242 · Cited by 309
Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man
Dentino, M. E., Luft, F. C., Yum, M. N., Williams, S. D., & Einhorn, L. H. (1978) · Cancer · Cited by 305
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
Zutphen, S. V., & Reedijk, J. (2005) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2005.03.005 · Cited by 295
Packer, R. J., Zhou, T., Holmes, E., Vezina, G., & Gajjar, A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos267 · Cited by 287
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
Launay‐Vacher, V., Rey, J., Bagnis, C. I., Deray, G., & Daouphars, M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0711-0 · Cited by 282
TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure
Ramesh, G., & Reeves, W. B. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00101.2003 · Cited by 282
Ototoxicity: therapeutic opportunities
Rybak, L. P., & Whitworth, C. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03552-x · Cited by 279
Gill, J. S., & Windebank, A. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1130 · Cited by 278
Megyesi, J., Safirstein, R. L., & Price, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1497 · Cited by 272
Renal Response to Tissue Injury: Lessons from Heme Oxygenase-1 Gene Ablation and Expression
AGARWAL, A., & NICK, H. S. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v115965 · Cited by 272
Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and Ormaplatin
Cornelison, T. L., & Reed, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1184 · Cited by 270
Silymarin Modulates Cisplatin-Induced Oxidative Stress and Hepatotoxicity in Rats
Mansour, H. H., Hafez, H. F., & Fahmy, N. M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.6.656 · Cited by 269
Functionalization of Platinum Complexes for Biomedical Applications
Wang, X., Wang, X., & Guo, Z. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00203 · Cited by 268
p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice
Ramesh, G., & Reeves, W. B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00401.2004 · Cited by 267
Kaushal, G. P., Kaushal, V., Hong, X., & Shah, S. V. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00026.x · Cited by 266
Nowak, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206373200 · Cited by 265
Agarwal, A., Balla, J., Alam, J., Croatt, A. J., & Nath, K. A. (1995) · Kidney International · doi:10.1038/ki.1995.414 · Cited by 260
Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies
El-Awady, E.-S. E., Moustafa, Y. M., Abo-Elmatty, D. M., & Radwan, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.085 · Cited by 260
Wang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., & Sadler, P. J. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200304724 · Cited by 254
Self-citationAn integrative view of the pathophysiological events leading to cisplatin nephrotoxicity
Sánchez-González, P. D., López-Hernández, F. J., López-Novoa, J. M., & Morales, A. I. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2011.602662 · Cited by 250
Tsuruya, K., Ninomiya, T., Tokumoto, M., Hirakawa, M., Masutani, K., Taniguchi, M., Fukuda, K., Kanai, H., Kishihara, K., Hirakata, H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00709.x · Cited by 241
Jo, S.-K., Cho, W. Y., Sung, S. A., Kim, H. K., & Won, N. H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67102.x · Cited by 235
Cisplatin Overdose: Toxicities and Management
Tsang, R. Y., Al-Fayea, T., & Au, H.-J. (2009) · Drug Safety · doi:10.2165/11316640-000000000-00000 · Cited by 235
Cisplatin nephrotoxicity: A review
Daugaard, G., & Abildgaard, U. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694330 · Cited by 234
Strumberg, D., Brügge, S., Korn, M. W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Möckel, C., Seeber, S., & Scheulen, M. E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf058 · Cited by 232
So, H., Kim, H., Lee, J.-H., Park, C., Kim, Y., Kim, E., Kim, J.-K., Yun, K.-J., Lee, K.-M., Lee, H.-Y., et al. (2007) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-007-0084-9 · Cited by 230
McDonald, E. S., Randon, K. R., Knight, A., & Windebank, A. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.013 · Cited by 227
Dugbartey, G. J., Peppone, L. J., & de Graaf, I. A. M. (2016) · Toxicology · doi:10.1016/j.tox.2016.10.001 · Cited by 226
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation
Lee, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3751 · Cited by 224
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity
Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T., & Inui, K.-I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.019 · Cited by 221
Error-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 219
Dickey, D. T., Wu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087601 · Cited by 219
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
Pinzani, V., Bressolle, F., Johanne Haug, I., Galtier, M., Blayac, J. P., & Balm�s, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686277 · Cited by 217
Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells
Arany, I., Megyesi, J. K., Kaneto, H., Price, P. M., & Safirstein, R. L. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00112.2004 · Cited by 215
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 209
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Albertella, M. R., Green, C. M., Lehmann, A. R., & O'Connor, M. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1095 · Cited by 207
Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways
Devarajan, P., Savoca, M., Castaneda, M. P., Park, M. S., Esteban-Cruciani, N., Kalinec, G., & Kalinec, F. (2002) · Hearing Research · doi:10.1016/s0378-5955(02)00634-2 · Cited by 204
Long-term toxicity of cisplatin in germ-cell tumor survivors
Chovanec, M., Abu Zaid, M., Hanna, N., El-Kouri, N., Einhorn, L. H., & Albany, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx360 · Cited by 204
Wang, J., Ladrech, S., Pujol, R., Brabet, P., Van De Water, T. R., & Puel, J.-L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1581 · Cited by 203
Gurney, J. G., Tersak, J. M., Ness, K. K., Landier, W., Matthay, K. K., & Schmidt, M. L. (2007) · Pediatrics · doi:10.1542/peds.2007-0178 · Cited by 201
Jimenez-Andrade, J. M., Herrera, M. B., Ghilardi, J. R., Vardanyan, M., Melemedjian, O. K., & Mantyh, P. W. (2008) · Molecular Pain · doi:10.1186/1744-8069-4-10 · Cited by 198
Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α
Ramesh, G., & Reeves, W. B. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00413.x · Cited by 196
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer
Cullen, K. J., Yang, Z., Schumaker, L., & Guo, Z. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9059-5 · Cited by 194
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190
Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421365112 · Cited by 188
Wu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075119 · Cited by 183
Endoplasmic Reticulum Stress–Associated Caspase 12 Mediates Cisplatin-Induced LLC-PK1 Cell Apoptosis
Liu, H., & Baliga, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090768 · Cited by 182
Boot, A., Huang, M. N., Ng, A. W. T., Ho, S.-C., Lim, J. Q., Kawakami, Y., Chayama, K., Teh, B. T., Nakagawa, H., & Rozen, S. G. (2018) · Genome Research · doi:10.1101/gr.230219.117 · Cited by 181
Oxaliplatin clinical activity: a review
Misset, J. L., Bleiberg, H., Sutherland, W., Bekradda, M., & Cvitkovic, E. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00070-6 · Cited by 180
Nephrotoxicity of platinum complexes is related to basolateral organic cation transport
Ludwig, T., Riethmüller, C., Gekle, M., Schwerdt, G., & Oberleithner, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00720.x · Cited by 179
Role of the Copper Transporter, CTR1, in Platinum-Induced Ototoxicity
More, S. S., Akil, O., Ianculescu, A. G., Geier, E. G., Lustig, L. R., & Giacomini, K. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-10.2010 · Cited by 176
l-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine
Chang, B., Nishikawa, M., Sato, E., Utsumi, K., & Inoue, M. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00342-9 · Cited by 175
Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity
Jiang, M., Yi, X., Hsu, S., Wang, C.-Y., & Dong, Z. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00262.2004 · Cited by 175
Kim, B.-E., Turski, M. L., Nose, Y., Casad, M., Rockman, H. A., & Thiele, D. J. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.003 · Cited by 174
Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity
Park, S. B., Goldstein, D., Lin, C. S.-Y., Krishnan, A. V., Friedlander, M. L., & Kiernan, M. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3425 · Cited by 174
Relationship Between Cisplatin Administration and the Development of Ototoxicity
Rademaker-Lakhai, J. M., Crul, M., Zuur, L., Baas, P., Beijnen, J. H., Simis, Y. J. W., van Zandwijk, N., & Schellens, J. H. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.077 · Cited by 174
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D., & Vauthey, J.-N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 173
Liu, H., & Baliga, R. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00908.x · Cited by 171
Role of ERK activation in cisplatin‐induced apoptosis in OK renal epithelial cells
Kim, Y. K., Kim, H. J., Kwon, C. H., Kim, J. H., Woo, J. S., Jung, J. S., & Kim, J. M. (2005) · Journal of Applied Toxicology · doi:10.1002/jat.1081 · Cited by 167
Lynch, E. D., Gu, R., Pierce, C., & Kil, J. (2005) · Hearing Research · doi:10.1016/j.heares.2004.08.002 · Cited by 167
Shahid, F., Farooqui, Z., & Khan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.009 · Cited by 166
Santos, N. A. G., Bezerra, C. S. C., Martins, N. M., Curti, C., Bianchi, M. L. P., & Santos, A. C. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0459-y · Cited by 165
Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity
Jiang, M., & Dong, Z. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139162 · Cited by 162
Khan, R., Khan, A. Q., Qamar, W., Lateef, A., Tahir, M., Rehman, M. U., Ali, F., & Sultana, S. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.11.013 · Cited by 160
Zhang, M., Liu, W., Ding, D., & Salvi, R. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00286-0 · Cited by 157
An overview of transcriptional regulation in response to toxicological insult
Jennings, P., Limonciel, A., Felice, L., & Leonard, M. O. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0919-y · Cited by 156
Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure
Portilla, D., Dai, G., McClure, T., Bates, L. M., Kurten, R. C., Megyesi, J. K., Price, P. M., & Li, S. (2002) · Kidney International · doi:10.1111/j.1523-1755.2002.kid553.x · Cited by 155
Risk factors for cisplatin‐associated ototoxicity in pediatric oncology patients
Yancey, A. M., Harris, M. S., Egbelakin, A., Gilbert, J. L., Pisoni, D. B., & Renbarger, J. L. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24138 · Cited by 154
Renal Dendritic Cells Ameliorate Nephrotoxic Acute Kidney Injury
Tadagavadi, R. K., & Reeves, W. B. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009040407 · Cited by 154
The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure
Megyesi, J. K., Udvarhelyi, N., Safirstein, R. L., & Price, P. M. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.271.6.f1211 · Cited by 153
Dzagnidze, A., Katsarava, Z., Makhalova, J., Liedert, B., Yoon, M., Kaube, H., Limmroth, V., & Thomale, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0523-07.2007 · Cited by 152
Lee, R. H., Song, J. M., Park, M. Y., Kang, S. K., Kim, Y. K., & Jung, J. S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00748-1 · Cited by 150
Jiang, M., Wei, Q., Pabla, N., Dong, G., Wang, C., Yang, T., Smith, S. B., & Dong, Z. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.010 · Cited by 149
Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma
Kushner, B. H., Budnick, A. S., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Cancer · doi:10.1002/cncr.22004 · Cited by 141
Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway
Jiang, M., Wang, C., Huang, S., Yang, T., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90579.2008 · Cited by 140
Pussegoda, K., Ross, C. J., Visscher, H., Yazdanpanah, M., Brooks, B., Rassekh, S. R., Zada, Y. F., Dubé, M., Carleton, B., & Hayden, M. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.80 · Cited by 136
Protection of renal cells from cisplatin toxicity by cell cycle inhibitors
Price, P. M., Safirstein, R. L., & Megyesi, J. K. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00192.2003 · Cited by 134
Wilmes, A., Bielow, C., Ranninger, C., Bellwon, P., Aschauer, L., Limonciel, A., Chassaigne, H., Kristl, T., Aiche, S., Huber, C. G., et al. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.10.006 · Cited by 132
Chowdhury, S., Sinha, K., Banerjee, S., & Sil, P. C. (2016) · BioFactors · doi:10.1002/biof.1301 · Cited by 131
Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity
Townsend, D. M., Tew, K. D., He, L., King, J. B., & Hanigan, M. H. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.08.004 · Cited by 130
Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity
Sofia Waissbluth, A., & Daniel, S. J. (2013) · Hearing Research · doi:10.1016/j.heares.2013.02.002 · Cited by 128
Guo, W., Zheng, W., Luo, Q., Li, X., Zhao, Y., Xiong, S., & Wang, F. (2013) · Inorganic Chemistry · doi:10.1021/ic4002626 · Cited by 125
Self-citationReversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Benkafadar, N., Menardo, J., Bourien, J., Nouvian, R., François, F., Decaudin, D., Maiorano, D., Puel, J., & Wang, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606230 · Cited by 112
Issues, indications, and controversies regarding intratympanic steroid perfusion
Hamid, M. A., & Trune, D. R. (2008) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0b013e32830ce796 · Cited by 111
Dependence of Cisplatin-Induced Cell Death In Vitro and In Vivo on Cyclin-Dependent Kinase 2
Price, P. M., Yu, F. Z., Kaldis, P., Aleem, E. A., Nowak, G. D. A., Safirstein, R. L., & Megyesi, J. K. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020162 · Cited by 111
El‐Sawalhi, M. M., & Ahmed, L. A. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.11.008 · Cited by 109
Iwata, K., Aizawa, K., Kamitsu, S., Jingami, S., Fukunaga, E., Yoshida, M., Yoshimura, M., Hamada, A., & Saito, H. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0638-y · Cited by 107
Membrane Transporters as Mediators of Cisplatin Effects and Side Effects
Ciarimboli, G. (2012) · Scientifica · doi:10.6064/2012/473829 · Cited by 105
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub3 · Cited by 104
Richiardi, L., Scélo, G., Boffetta, P., Hemminki, K., Pukkala, ., Olsen, J. H., Weiderpass, E., Tracey, E. A., Brewster, D., McBride, M. L., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22345 · Cited by 102
Omar, H. A., Mohamed, W. R., Arafa, E. A., Shehata, B. A., Sherbiny, G. A. E., Arab, H. H., & Elgendy, A. N. A. M. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.09.007 · Cited by 100
Yang, C., Kaushal, V., Haun, R. S., Seth, R., Shah, S. V., & Kaushal, G. P. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402287 · Cited by 100
Base‐Resolution Analysis of Cisplatin–DNA Adducts at the Genome Scale
Shu, X., Xiong, X., Song, J., He, C., & Yi, C. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201607380 · Cited by 96
Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity
Quintanilha, J. C. F., de Sousa, V. M., Visacri, M. B., Amaral, L. S., Santos, R. M. M., Zambrano, T., Salazar, L. A., & Moriel, P. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3358-x · Cited by 95
Li, S., Bhatt, R., Megyesi, J. K., Gökden, N., Shah, S. V., & Portilla, D. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00206.2004 · Cited by 94
Li, S., Wu, P., Yarlagadda, P., Vadjunec, N. M., Proia, A. D., Harris, R. A., & Portilla, D. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00190.2003 · Cited by 92
Effect of JNK inhibition on cisplatin-induced renal damage
Francescato, H. D. C., Costa, R. S., Junior, F. B., & Coimbra, T. M. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm144 · Cited by 91
The anticancer drug cisplatin can cross-link the interdomain zinc site on human albumin
Hu, W., Luo, Q., Wu, K., Li, X., Wang, F., Chen, Y., Ma, X., Wang, J., Liu, J., Xiong, S., et al. (2011) · Chemical Communications · doi:10.1039/c1cc11627d · Cited by 89
Self-citationLee, J. E., Nakagawa, T., Kim, T. S., Endo, T., Shiga, A., Iguchi, F., Lee, S. H., & Ito, J. (2004) · Acta Oto-Laryngologica · doi:10.1080/00016480410017521 · Cited by 87
Treskes, M., Nijtmans, L. G. J., Fichtinger-Schepman, A. M. J., & van der Vijgh, W. J. F. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90607-k · Cited by 80
Cisplatin hepatotoxicity mediated by mitochondrial stress
Waseem, M., Bhardwaj, M., Tabassum, H., Raisuddin, S., & Parvez, S. (2015) · Drug and Chemical Toxicology · doi:10.3109/01480545.2014.992437 · Cited by 78
Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure
Megyesi, J. K., Andrade, L., Vieira, J. M., Safirstein, R. L., & Price, P. M. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00078.2002 · Cited by 75
Yu, F. H. Z., Megyesi, J. K., Safirstein, R. L., & Price, P. M. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00101.2005 · Cited by 71
Schaaf, G., Maas-Bakker, R. F., de Groene, E. M., & Fink‐Gremmels, J. (2002) · Free Radical Research · doi:10.1080/1071576021000005267 · Cited by 71
Chen, S., Huo, X., Lin, Y., Ban, H., Lin, Y., Li, W., Zhang, B., Au, W. W., & Xu, X. (2010) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2010.01.004 · Cited by 68
Transtympanic perfusion: indications and limitations
Light, J. P., & Silverstein, H. (2004) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/01.moo.0000134438.91734.38 · Cited by 64
Long-Term Renal Effect of Cisplatin in Man
Brilleta, G., Demya, G., Jacquiauda, C., et al. (1994) · American Journal of Nephrology · doi:10.1159/000168693 · Cited by 64
Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?
Oun, R., & Rowan, E. G. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.063 · Cited by 64
Rizzo, A. A., Vassel, F.-M., Chatterjee, N., D’Souza, S., Li, Y., Hao, B., Hemann, M. T., Walker, G. C., & Korzhnev, D. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801149115 · Cited by 64
Depletion of Mitofusin-2 Causes Mitochondrial Damage in Cisplatin-Induced Neuropathy
Bobylev, I., Joshi, A. R., Barham, M., Neiss, W. F., & Lehmann, H. C. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0364-7 · Cited by 61
Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
Hu, S., Leblanc, A. F., Gibson, A., Hong, K., Kim, J., Janke, L. J., Li, L., Vasilyeva, A. N., Finkelstein, D., Sprowl, J. A., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12480 · Cited by 60
Razzaque, M. S., Koji, T., Kumatori, A., et al. (1999) · Histochemistry and Cell Biology · doi:10.1007/s004180050368 · Cited by 59
Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats
Tomaszewski, A., & Büsselberg, D. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.07.005 · Cited by 55
Cisplatin nephrotoxicity affects magnesium and calcium metabolism
Goren, M. P. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10335 · Cited by 55
Drögemöller, B. I., Monzon, J. G., Bhavsar, A. P., Borrie, A. E., Brooks, B., Wright, G. E. B., Liu, G., Renouf, D. J., Kollmannsberger, C., Bedard, P. L., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0502 · Cited by 55
Induction of Renal Endonuclease G by Cisplatin Is Reduced in DNase I-Deficient Mice
Yin, X., Apostolov, E. O., Shah, S. V., Wang, X., Bogdanov, K. V., Buzder, T., Stewart, A. G., & Basnakian, A. G. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080896 · Cited by 54
Ko, J., Lee, I., Park, S.-H., Moon, C., Kang, S. S., Kim, S., & Kim, J.-C. (2014) · Laboratory Animal Research · doi:10.5625/lar.2014.30.4.174 · Cited by 51
Kratochwil, N. A., Ivanov, A. I., Patriarca, M., Parkinson, J. A., Gouldsworthy, A. M., Murdoch, P. D. S., & Sadler, P. J. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990768n · Cited by 51
Brown, A. L., Lupo, P. J., Okcu, M. F., Lau, C. C., Rednam, S. P., & Scheurer, M. E. (2015) · Cancer Medicine · doi:10.1002/cam4.516 · Cited by 50
Moreno-Gordaliza, E., Esteban‐Fernández, D., Lázaro, A., Humanes, B., Aboulmagd, S., Tejedor, A., Linscheid, M. W., & Gómez-Gómez, M. M. (2016) · Talanta · doi:10.1016/j.talanta.2016.11.026 · Cited by 49
Song, K. I., Park, J. T., Lee, S., Lee, D., Jang, H.-J., Kim, S., Ko, H., Kim, H. J., Lee, J. Y., Hwang, G. S., et al. (2015) · Planta Medica · doi:10.1055/s-0035-1545696 · Cited by 46
Yan, F., Liu, J. J., Ip, V., Jamieson, S. M. F., & McKeage, M. J. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13355 · Cited by 43
Bearcroft, C. P., Domizio, P., Mourad, F. H., et al. (1999) · Gut · doi:10.1136/gut.44.2.174 · Cited by 43
Pini, A., Garella, R., Idrizaj, E., Calosi, L., Baccari, M. C., & Vannucchi, M. G. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12712 · Cited by 42
Aleisa, A. M., Al‐Majed, A. A., Al‐Yahya, A. A., Al-Rejaie, S. S., Bakheet, S. A., Al‐Shabanah, O. A., & Sayed‐Ahmed, M. M. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04714.x · Cited by 41
Rosic, G. L., Selaković, D., Joksimović, J., Srejovic, I. M., Zivkovic, V. I., Tatalović, N., Oreščanin-Dušić, Z., Mitrović, S., Ilić, M., & Jakovljevic, V. L. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.11.028 · Cited by 38
Waseem, M., Pandey, P., Tomar, B., Raisuddin, S., & Parvez, S. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.07.006 · Cited by 37
Anbazhagan, A. N., Priyamvada, S., & Mahmood, R. (2011) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2011.05.004 · Cited by 35
Infliximab Modulates Cisplatin-Induced Hepatotoxicity in Rats
Cüre, M. C., Cüre, E., Kalkan, Y., Kırbaş, A., Tümkaya, L., Yılmaz, A., Türkyılmaz, A. K., Şehitoğlu, İ., & Yuce, S. (2016) · Balkan Medical Journal · doi:10.5152/balkanmedj.2016.150576 · Cited by 32
Anders, J. C., Grigsby, P. W., & Singh, A. K. (2006) · Radiation Oncology · doi:10.1186/1748-717x-1-14 · Cited by 31
Kwon, H. N., Park, J., An, Y., Sim, J., & Park, S. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.08.006 · Cited by 25
Shahid, F., Farooqui, Z., Abidi, S., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.044 · Cited by 23
Tan, A. C., & Marx, G. M. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-222948 · Cited by 11
Cancer cachexia: Are we ready to take a step forward?
Crawford, J. (2017) · Cancer · doi:10.1002/cncr.31126 · Cited by 9
Cited by
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Wang, J., Nie, J.-J., Guo, P., Yan, Z., Yu, B., & Bu, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11013 · Cited by 66
Hernández-Rangel, A. E., Cabrera-Licona, A., Hernandez-Fuentes, G. A., Beas-Guzmán, O. F., Martínez-Martínez, F. J., Alcalá-Pérez, M. A., Montes-Galindo, D. A., Rodriguez-Sanchez, I. P., Martinez-Fierro, M. L., Casarez-Price, J. C., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081804 · Cited by 7
Metadata
- Authors
- Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-07-29
- Volume
- 32
- Issue
- 8
- Pages
- 1469-1486
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2965008467
- Cited by
- 440
- References
- 197
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.